Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy |
Jo, Hyoung
(Functional Food Center, Korea Institute of Science and Technology (KIST) Gangneung Institute)
Jung, Sang Hoon (Functional Food Center, Korea Institute of Science and Technology (KIST) Gangneung Institute) Kang, Jun (Department of Pathology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) Yim, Hye Bin (Department of Ophthalmology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) Kang, Kui Dong (Department of Ophthalmology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) |
1 | Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L. and Smith, L. E. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U. S. A. 92, 10457-10461. DOI ScienceOn |
2 | Kim, J, Kim, S. J., Chang, Y. S. and Park, W. S. (2014) Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina 34, 77-82. DOI |
3 | Simpson, J. L., Melia, M., Yang, M. B., Buffenn, A. N., Chiang, M. F. and Lambert, S. R. (2012) Current role of cryotherapy in retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology 119, 873-877. DOI ScienceOn |
4 | Condorelli, M., Chiariello, M., Dagianti, A., Penco, M., Dalla Volta, S., Pengo, V., Schivazappa, L., Mattioli, G., Mattioli, A. V. and Brusoni, B. (1994) IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J. Am. Coll. Cardiol. 23, 27-34. DOI ScienceOn |
5 | Lasierra-Cirujeda, J., Coronel, P., Aza, M. and Gimeno, M. (2010) Use of sulodexide in patients with peripheral vascular disease. J. Blood Med. 1, 105-115. |
6 | Kristova, V., Liskova, S., Sotnikova, R., Vojtko, R. and Kurtansky, A. (2008) Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol. Res. 57, 491-494. |
7 | Corbu, C., Predoi, D. and Goicea, D. (1996) Sulodexide treatment in retinal vein obstructions. Oftalmologia 40, 393-397. |
8 | Weiss, R., Niecestro, R. and Raz, I. (2007) The role of sulodexide in the treatment of diabetic nephropathy. Drugs 67, 2681-2696. DOI ScienceOn |
9 | Harenberg, J. (1998) Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med. Res. Rev. 18, 1-20. DOI ScienceOn |
10 | Oshima, Y., Oshima, S., Nambu, H., Kachi, S., Hackett, S. F., Melia, M., Kaleko, M., Connelly, S., Esumi, N., Zack, D. J. and Campochiaro, P. A. (2004) Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J. Cell Physiol. 201, 393-400. DOI ScienceOn |
11 | Hollborn, M., Stathopoulos, C., Steffen, A., Wiedemann, P., Kohen, L. and Bringmann, A. (2007) Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest. Ophthalmol. Vis. Sci. 48, 4360-4367. DOI ScienceOn |
12 | Lauver, D. A. and Lucchesi, B. R. (2006) Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc. Drug Rev. 24, 214-226. DOI ScienceOn |
13 | Pletinck, A., Van Landschoot, M., Steppan, S., Laukens, D., Passlick-Deetjen, J., Vanholder, R. and Van Biesen, W. (2012) Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol. Dial. Transplant. 27, 548-556. DOI ScienceOn |
14 | Simonetti, O., Lucarini, G., Brancorsini, D., Nita, P., Bernardini, M. L., Biagini, G. and Offidani, A. (2002) Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95, 1963-1970. DOI ScienceOn |
15 | Yafai, Y., Iandiev, I., Wiedemann, P., Reichenbach, A. and Eichler, W. (2004) Retinal endothelial angiogenic activity: effects of hypoxia and glial (Muller) cells. Microcirculation 11, 577-586. DOI ScienceOn |
16 | Pennock, S. and Kazlauskas, A. (2012) Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol. Cell Biol. 32, 1955-1966. DOI |
17 | DeNiro, M., Al-Mohanna, F. H. and Al-Mohanna, F. A. (2011) Inhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy. PLoS One 6, e22244. DOI |
18 | Packham, D. K., Wolfe, R., Reutens, A. T., Berl, T., Heerspink, H. L., Rohde, R., Ivory, S., Lewis, J., Raz, I., Wiegmann, T. B., Chan, J. C., de Zeeuw, D., Lewis, E. J. and Atkins, R. C. (2012) Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123-130. DOI |
19 | Gambaro, G., Kinalska, I., Oksa, A., Pont'uch, P., Hertlova, M., Olsovsky, J., Manitius, J., Fedele, D., Czekalski, S., Perusicova, J., Skrha, J., Taton, J., Grzeszczak, W. and Crepaldi, G. (2002) Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 13, 1615-1625. DOI ScienceOn |
20 | Broekhuizen, L. N., Lemkes, B. A., Mooij, H. L., Meuwese, M. C., Verberne, H., Holleman, F., Schlingemann, R. O., Nieuwdorp, M., Stroes, E. S. and Vink, H. (2010) Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53, 2646-2655. DOI |
21 | Kim, N. H., Oh, J. H., Seo, J. A., Lee, K. W., Kim, S. G., Choi, K. M., Baik, S. H., Choi, D. S., Kang, Y. S., Han, S. Y., Han, K. H., Ji, Y. H. and Cha, D. R. (2005) Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 67, 167-177. DOI ScienceOn |
22 | Smith, L. E., Wesolowski, E., McLellan, A., Kostyk, S. K., D'Amato, R., Sullivan, R. and D'Amore, P. A. (1994) Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35, 101-111. |
23 | Li, S., Li, T., Luo, Y., Yu, H., Sun, Y., Zhou, H., Liang, X., Huang, J. and Tang, S. (2011) Retro-orbital injection of FITC-dextran is an effective and economical method for observing mouse retinal vessels. Mol. Vis. 17, 3566-3573. |
24 | Watanabe, D., Suzuma, K., Suzuma, I., Ohashi, H., Ojima, T., Kurimoto, M., Murakami, T., Kimura, T. and Takagi, H. (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139, 476-481. DOI ScienceOn |
25 | Nanni, C., Pettinato, C., Ambrosini, V., Spinelli, A., Trespidi, S., Rubello, D., Al-Nahhas, A., Franchi, R., Alavi, A. and Fanti, S. (2007) Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl. Med. Commun. 28, 547-553. DOI ScienceOn |
26 | Connor, K. M., Krah, N. M., Dennison, R. J., Aderman, C. M., Chen, J., Guerin, K. I., Sapieha, P., Stahl, A., Willett, K. L. and Smith, L. E. (2009) Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 4, 1565-1573. DOI ScienceOn |